Journal profile · Multiple
Genes & Diseases
ISSN 2352-4820 · eISSN 2352-3042 · ELSEVIER · PEOPLES R CHINA · Quarterly · Founded 2014
Genes & Diseases: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 14.46; fully open access; APC about USD 2,500; median 155 days to acceptance (112 articles, last 24 months); 453 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Genes & Diseases is published by ELSEVIER and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are RNA modifications and cancer, Cancer-related molecular mechanisms research and Epigenetics and DNA Methylation, together about 26% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Main research topics OpenAlex counts of recent articles; shares are approximate
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology11.8%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology8.2%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology6.1%
- Ferroptosis and cancer prognosisMedicine5.6%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5.4%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology5.1%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology4.9%
- Cancer-related gene regulationBiochemistry, Genetics and Molecular Biology4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Biochemistry & Molecular Biology | Zone 1 |
| Minor | Genetics & Heredity | Zone 1 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 14.46LetPub ·
- Impact factor (publisher)
- 14.6Publisher website ·
- CiteScore 2026-06
- 10.4LetPub ·
- CiteScore (publisher)
- 10.4Publisher website ·
- SJR 2026-06
- 1.78LetPub ·
- SNIP 2026-06
- 1.44LetPub ·
- h-index
- 92OpenAlex ·
- i10-index
- 741OpenAlex ·
- 2-year mean citedness
- 2.16OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 98.09%LetPub ·
Volume
- Articles per year
- 209LetPub ·
Articles by year OpenAlex count · 2,345 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 433 | 433 | 76 |
| 2025 | 453 | 453 | 1,027 |
| 2024 | 242 | 242 | 1,336 |
| 2023 | 385 | 385 | 4,953 |
| 2022 | 268 | 268 | 7,161 |
| 2021 | 105 | 105 | 3,569 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
155 daysMedian, submission to acceptance · P25–P75 103 days – 248 days
- Acceptance to online
- median 38 days (112 articles)
- Submission to online
- median 206 days
- Sample
- 112 articles with submission and acceptance dates (802 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2.3 weeksLetPub ·
- Average acceptance (community reports)
- 14%LetPub ·
- Submission to first decision
- 20 daysPublisher website ·
- First decision after review
- 67 daysPublisher website ·
- Submission to final decision
- 7 daysPublisher website ·
- Submission to acceptance
- 173 daysPublisher website ·
- Acceptance to publication
- 37 daysPublisher website ·
- Peer review
- Anonymous peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,500 | — | — | |
| LetPub | USD 2,500 | No | — | |
| Publisher website | USD 3,000 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers2, by deadline
Publisher websiteWhat to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 5
- Manuscript length
- ≤ 6,000 words
- Reference style
- AMA
- Suggested reviewers
- Required, 3
- Cover letter
- Required
Article types accepted6, with length limits
- commentaryCommentary is a commissioned analysis of recently published paper (published in either Genes & Diseases and/or other top-tier journals) of immediate interest.Ab…main text ≤ 1,000 words · references ≤ 1
- correspondenceCorrespondence may be accepted for publication after a fast-track editorial review. It would be comments or criticisms relevant to a paper published in Genes & …main text ≤ 1,000 words · references ≤ 1
- editorialAll manuscripts received are duly acknowledged. Upon submission, the Editorial Office will check the manuscript's conformity to technical quality and author gui…Length not stated
- letterLetters provide rapid and concise report of a novel finding that is brief in nature but is of general interest to the field. Abstract: None / Start with a salut…main text ≤ 1,200 words · references ≤ 1
- rapid communicationRapid communication documents high impact early findings that are brief in nature and with an urgent dissemination need for the scientific community. Abstract: …main text ≤ 1,200 words · references ≤ 1
- review articleReviews provide an insightful overview of the recent advances in a particular field or area in experimental and translational medical research interesting to th…main text ≤ 250 words · abstract ≤ 250 words · references ≤ 6
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Plagiarism, Preprints
- Authorship Author contributions
For transparency, we encourage corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles describing each contributor's specific contribution to the scholarly output. The roles are: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administratio…
Source ↗Publisher website ·- Conflicts of interest Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places:…
Source ↗Publisher website ·- Publication ethics Ethical Approval
For manuscripts reporting studies involving human subjects, statements identifying the committee approving the studies and confirming that informed consent was obtained from all subjects must appear in the Experimental Procedures section. All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant institutional and national guidelines and regulations. …
Source ↗Publisher website ·- License & copyright Copyright
Copyright retained by authors with exclusive licensing to KeAi Model summary
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement'. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.Author rightsFor open access publishing, this journal uses an exclusive licensing agreement. Authors will retai…
Source ↗Publisher website ·- Open access Open access
Open access journal Model summary
Genes & Diseases is a peer reviewed, open access journal. To provide open access, the journal has an open access fee (also known as article publishing charge, APC) paid by the authors or on their behalf (e.g. by their research funders or institution), either in the US dollar (USD $) or the Chinese currency RMB. The Article Processing Charge (APC) for the accepted manuscripts submitted on and after…
Source ↗Publisher website ·- Peer review Peer Review
Single blind peer review Model summary
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is f…
Source ↗Publisher website ·- Plagiarism
Plagiarism screening via Crossref Similarity Check Model summary
To verify compliance, your article may be checked by Crossref Similarity Check and other originality or duplicate checking software.
Source ↗Publisher website ·- Preprints Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the nam…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- ELSEVIER
- Country or region
- PEOPLES R CHINA
- Language
- English
- Frequency
- Quarterly
- Founded
- 2014
- ISSN
- 2352-4820
- Electronic ISSN
- 2352-3042
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Genes & Diseases
What CAS zone is Genes & Diseases in?
In the 2025 upgraded edition of the CAS Journal Ranking, Genes & Diseases is in Zone 2 of Medicine, and in Zone 2 of the minor category Biochemistry & Molecular Biology / Genetics & Heredity. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Genes & Diseases?
The latest impact factor listed by LetPub is 14.46; CiteScore 10.4, h-index 92.
How long does peer review take at Genes & Diseases?
Based on the dates recorded on 112 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 155 days (interquartile range 103–248 days); authors report an average review time of about 2.3 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Genes & Diseases?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 5; Manuscript length: ≤ 6,000 words; Reference style: AMA; Suggested reviewers: Required, 3; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Genes & Diseases?
According to LetPub and DOAJ records, Genes & Diseases is indexed in SCIE, Scopus and DOAJ.
Is Genes & Diseases open access, and what is the APC?
Genes & Diseases is a fully open-access journal. APC about USD 2,500.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .